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Summary
Based on experience from the treatment of other autoimmune dis-
eases and because of the limitations imposed by existing therapeu-
tic options for Graves’ disease (GD) and thyroid-associated
ophthalmopathy (TAO), rituximab (RTX) was recently proposed
as a novel therapy option. Here, we summarize the rationale for
using RTX; give an overview of the possible mechanisms of action;
and give an account of its effects and side-effects when used in GD
and TAO. Scant evidence, originating from only a few methodolog-
ically inhomogeneous studies, suggests that RTX may prolong
remission for hyperthyroidism over that seen with antithyroid
drugs, at least in mild GD. Furthermore, in patients with TAO,
who are unresponsive to conventional immunosuppressive ther-
apy, RTX seems efficacious. As we wait for larger-scale randomized
studies, RTX, should be considered experimental and reserved for
patients who do not respond favourably to conventional therapy. It
is the first in what is likely to be a series of new and emerging treat-
ments specifically targeting relevant components of the immune
system. Further studies will hopefully lead to improved and better
tailored, individualized therapy for GD and especially TAO.
(Received 9 March 2010; returned for revision 14 March 2010;
finally revised 20 March 2010; accepted 22 March 2010)
Graves’ disease (GD) afflicts approximately 1–2% in the adult pop-
ulation.1,2 Its aetiology is incompletely understood and thought to
result from a complicated interaction between genetic susceptibil-
ity and environmental factors.3 This interplay might explain its epi-
demiologic pattern, including geographical variations in
prevalence.3 It is likely that the vast majority of clinicians will at
some time during their practice encounter patients with GD, as the
disease can be associated with symptoms from a number of organ
systems. During the last 50 years, relatively little advance has
been made in improving the therapy of this debilitating disease.4
Therapeutic options for the hyperthyroidism associated with GD –
antithyroid drugs, radioiodine therapy and surgical thyroidectomy
– allow us to care well for patients with the glandular aspects of the
disease. Moreover, adequate data concerning efficacy, side-effect
profiles, important prognostic factors (e.g. thyroid size, level of
thyroid-stimulating hormone receptor antibodies [TRAbs] and
smoking habits) and better patient education have improved our
overall ability to individualize therapy and to obtain good clinical
outcomes. However, achieving cure of the underlying autoimmune
disease in a safe and cost-effective manner remains elusive in the
majority of patients. Recurrence rate following antithyroid drugs is
usually more than 50%. Eventually, the majority of patients treated
with radioiodine become hypothyroid as does many of those
undergoing surgical or radioiodine ablation. Therefore, it is not
surprising that consensus as to the best therapy for achieving
euthyroidy has been difficult to reach.2,4,5
Regarding the most incapacitating manifestation of GD, thy-
roid-associated ophthalmopathy (TAO; also called Graves’ orbi-
topathy), progress in improving therapy has been even more
difficult.6,7 The established methods of treatment, including oral or
intravenous glucocorticoids, orbital irradiation, surgical decom-
pression or a combination of these, offer only incremental
improvement compared with allowing the disease to take its natu-
ral course. Cost-effectiveness is poor and the improvement of qual-
ity of life during and following therapy remains modest.8 Offering
patients with GD counselling regarding the pros and cons of
radioiodine ablative therapy and cessation of cigarette smoking has
positively impacted the prognosis of TAO when considering the
cost-effectiveness of intervention.
Since the initial observations dating to 2006, we9 and others10
have reported the beneficial effects in GD of B-cell depletion with
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the therapeutic antibody rituximab (RTX). These and subsequent
studies have suggested that RTX may benefit patients with GD as
well as those manifesting severe TAO. In the following article, we
briefly update the potential mechanisms of action of this drug and
attempt to dissect the impact of therapy on thyroid function and
the clinical behaviour of TAO. Despite favourable initial reports, in
the light of the side-effects experienced by several investigators and
the substantial cost of RTX therapy, we have tempered our enthusi-
asm. We now emphasize the great need for additional and more
robust studies before we can recommend its use on a wider scale in
GD.
Rationale for the use of rituximab in GD (Fig. 1)
RTX is a human/murine chimeric monoclonal antibody, which tar-
gets CD20, a transmembrane protein, present on immature and
mature B cells, but absent on most pro-B cells and plasma cells.11 It
was originally utilized in the treatment of B-cell lymphomas, an
indication first identified in 1997 (reviewed in reference12). Subse-
quently, RTX proved useful in the treatment of a variety of autoim-
mune diseases.13 Among the first were IgM antibody-related
polyneuropathies in 199914 and rheumatoid arthritis (RA) in
2001.15 The rationale behind the use of RTX in these and allied dis-
eases remains the putative role of autoantibodies (i.e. rheumatoid
factors and, as subsequently shown, anticyclic citrullinated peptid
antibodies in RA) in their pathogenesis. It was believed that disrup-
tion of pathogenic autoantibody generation through B-cell deple-
tion would yield long-term remission.16 As GD is in part an
autoantibody-mediated disease where TRAbs (or more specifically
the stimulating fraction of TRAbs, known as TSAbs) are pathogno-
monic for GD, Hasselbalch17 and Wang and Baker,18 as the first,
suggested the potential benefit of RTX therapy in GD. In addition
to the thyroid-stimulating hormone and the antibodies directed
against it, the insulin-like growth factor receptor (IGF-1R) has been
demonstrated by one group to be over-expressed on orbital fibro-
blasts19 in TAO and its ligation by IGF-1 or IgG’s from patients
with GD results in the production of powerful T-cell chemoattrac-
tants.20 Moreover, both T and B lymphocytes are skewed towards
the IGF-1R+ phenotype, resulting in enhanced proliferation and
survival.21,22
In addition to their role as precursors for antibody-secreting
plasma cells, B cells are highly efficient antigen-presenting cells
(APCs).23 Studies using animal models of RA24 and type 1 diabetes
mellitus25,26 have pointed towards a critical role for B cells as APCs
in disease pathogenesis. Accordingly, a beneficial effect of RTX has
been demonstrated in classical T-cell-mediated autoimmune dis-
eases, such as multiple sclerosis27 and type 1 diabetes.28 Because
they can take up minute amounts of antigen via their high-affinity
antigen receptor, antigen-specific B cells are efficient APCs, even at
very low antigen concentrations.23 It should be noted that an (self)
antigen associated with IgG-containing immune complexes may
engage B cells expressing rheumatoid factor as antigen receptor in
antigen presentation.29 Moreover, as we have previously shown
regarding human thyroglobulin, B cells may take up self-antigen in
the context of complement-activating immune complexes, through
the complement receptor 2 (CR2, CD35), and in so doing, initiate
a T-cell response.30,31
In addition to their roles in antibody production and as APCs, B
cells are capable of producing a variety of cytokines. These include
pro-inflammatory cytokines such as IL-6, tumor necrosis factor-a
(TNF-a) and lymphotoxin,32–34 and anti-inflammatory cytokines
including IL-10 and transforming growth factor b (TGF-b).33–35
Recently, an IL-10-producing subset of B cells, known as regulatory
B cells (Bregs) or B10 cells, has been associated with protection
against experimental autoimmune encephalitis35 and arthritis.36
Moreover, B cells can induce T-cell anergy through their TGF-b
production.37 Somewhat paradoxically, B cells seem to play detri-
mental roles under certain conditions while exerting protective
effects in others. This may be explained by the protective actions of
B cells during the autoimmune disease induction, prior to their
pathogenic roles following disease initiation.38
In autoimmune thyroid disease (AITD), the gland often exhibits
a lymph node-like architecture, where germinal centres harbour
somatic hypermutation and affinity antibody maturation.39 These
germinal centres support the development of specific memory B
cells and plasma cells, and thyroid autoantibody generation.39,40
We have recently shown that B cells are completely absent from
thyroid and colon within 1 week and at 69 days, respectively, fol-
lowing RTX therapy.41,42 Moreover, others have shown the absence
of B cells from additional examples of inflamed tissue.43,44 Taken
together, these data indicate that RTX mediates complete B-cell
depletion in inflamed tissues manifesting autoimmune diseases by
disrupting germinal centres.
With regard to TAO, Salvi et al.10 reported an almost complete
absence of lymphocytes in an orbital biopsy taken 10 months after
RTX therapy. In contrast, we45 found that the B-cell content in the
orbital tissue following RTX in a patient with TAO was comparable
to that in another patient not receiving the therapy. It is unclear























Fig. 1 The multifaceted role of B cells in Graves’ disease (GD). Rituximab
specifically eliminates peripheral CD20+ B cells. B cells produce autoanti-
bodies to the TSHR and IGF-1R, which leads to hyperthyroidism and
potentially fibroblast activation. B and T cells from Graves’ patients display
increased expression of the IGF-1R and activation of this receptor via GD-
IgG enhances B-cell autoantibody production and T-cell survival. Further-
more, B cells are excellent antigen-presenting cells and produce cytokines
which may be central to immune infiltration and the exuberant inflamma-
tory response demonstrated in patients with GD.
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depletion or repopulation of lymphocytes. Clearly, additional
sampling, perhaps undertaken at earlier time points, will prove
necessary to establish the completeness and durability of RTX-
dependent B-cell depletion in orbital tissue.
The effect of rituximab on thyroid function
Three studies have been conducted examining the effect of RTX on
thyroid function in GD.46–48 We must acknowledge limited data
from the few patients thus far reported (Table 1). These prelimin-
ary observations currently preclude drawing any conclusions.
Thus, enthusiasm generated by the novelty and potential benefit of
RTX therapy in GD must be tempered by the shortcomings of each
of these studies. Many factors varied among individual patients
and between the three studies. Among them, duration of disease,
interval since diagnosis, primary disease vs recurrence, familial vs
sporadic AITD, duration and type of treatment for hyperthyroid-
ism, presence of TAO, initial thyroid size, TRAb levels, smoking
habits, RTX dose, follow-up intervals and inclusion of control sub-
jects all varied between the three studies.46–48
El Fassi et al.46 treated prospectively a group of 20 patients with
newly diagnosed but untreated hyperthyroidism with methimazole
(MMI) for approximately 4 months until they became euthyroid.
Ten of these were then treated with RTX, two of whom manifested
TAO. All were followed off MMI until hyperthyroidism recurred.
Within approximately 1 year, all the patients not receiving RTX
had relapsed, while 4 of 10 patients treated with RTX were euthy-
roid and have subsequently remained so for up to 30 months.
TRAb levels appear predictive of this sustained remission, as all
four had values below 5 IU/l. Further, in support of an effect of
RTX, all patients with similar low TRAb levels who did not receive
RTX relapsed within a year. Salvi et al.47 studied nine patients
(Table 1), of whom seven manifested TAO. At the time of RTX
therapy, four were hyperthyroid and had yet to be treated and
five were euthyroid. Among these five, some were in remission,
others were undergoing treatment with MMI or were receiving
levothyroxine following surgical thyroidectomy. Eight patients
were re-assessed 12 months after receiving RTX, while one was
re-examined 5 months later. The authors concluded that RTX
failed to affect thyroid function, as those in remission remained
euthyroid, while those who were hyperthyroid and remained
untreated showed no improvement in their thyroid function. These
were thus started on MMI. Finally, Heemstra et al.48 treated 13
patients with relapsing GD of whom three manifested mild TAO.
Ten patients were transiently treated with MMI. There was no
control group and follow-up examination occurred 26 weeks
following administration of 1 g of RTX i.v. twice with an interval
of 2 weeks. Four patients failed RTX treatment and received radio-
iodine therapy. Serum free-T4 concentrations declined while
serum TSH levels increased in the remaining nine patients with
normalization occurring in five. These nine patients have remained
euthyroid for a median of 18 (range 14–20) months since RTX
administration. Pretreatment levels of TRAb were relatively low
(median 4 IU/l, range 0Æ2–6Æ3), congruent with those reported in
the study of El Fassi et al.46 Despite the small number of patients
included and the lack of control subjects, the study of Heemstra
et al.48 taken together with ours46 suggests that RTX may influence
remission rates in GD, especially in patients with low TRAb levels.
The effect of rituximab on autoantibodies
El Fassi et al.46 demonstrated that TRAb levels decrease at similar
rates in patients regardless of whether they are receiving RTX as a
single agent (median 29%), RTX combined with MMI (36%) or
only MMI (64%) at 13 weeks. Subsequent levels were found to
decline in patients treated with RTX, while the levels remained rela-
tively constant in those not receiving the drug. Salvi et al.47 found a
mean decrease of 40% in TRAb levels in RTX-treated patients after
30 weeks, similar to that observed in patients treated with i.v.
glucocorticoids. In the study by Heemstra et al.,48 the median
TRAb levels of the nine responders decreased by 52% within
26 weeks following RTX administration. Thus, a moderate
decrease in TRAb levels occurred following RTX therapy in all three
studies, but the decline was similar to that in patients treated with
MMI or prednisolone.
The report by El Fassi et al.49 of a decrease (median 84%) in
cAMP production in TSHR-transfected CHO cells elicited by sera
collected from patients treated with RTX, strongly suggests that
TSAb activity had declined within 20 weeks of therapy. Those
patients not treated with RTX failed to exhibit a decrease despite
similar decreases in total TRAbs in the two groups.46 It remains
obscure how TSAb production can be specifically affected by RTX.
Table 1. Pertinent clinical data in patients with Graves’ disease (GD), with or without thyroid-associated ophthalmopathy (TAO), treated with rituximab.
Influence on thyroid function and TAO
Study and reference







El Fassi et al. 200746 10 F. 2 with TAO 375 mg/m2 weekly for 4 weeks Euthyroid 5 and 6 1 and 2 5 of 10 4 of 10*
Salvi et al. 200747 7 F; 2 M 7 with TAO 1 g twice with 2 week interval 4 hyperthyroid
5 euthyroid
Mean 4Æ7 Mean 1Æ8 3 of 9 NA
Heemstra et al. 200848 9 F; 4 M 3 with mild TAO 1 g twice with 2 week interval Hyperthyroid NA NA 2 of 13 9 of 13†
Khanna et al. 201066 4 F; 2 M All with TAO 1 g twice with 2 week interval Euthyroid Mean 5Æ3 Mean 1Æ8 3 of 6 NA
F, females; M, males; TAO, thyroid-associated ophthalmopathy; CAS, clinical activity score; NA, not applicable.
*Follow-up 14–30 months post rituximab therapy.
†Follow-up 14–30 months post rituximab.
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Certain specificities of autoreactive plasma cells are more short-
lived than plasma cells producing antimicrobial antibodies and dis-
appear more rapidly following B-cell depletion,50 and this may also
apply to TSAb-producing plasma cells. As expression of the TSH-
receptor can be up-regulated upon stimulation51 and the A subunit
of the receptor can be shed from thyroid cells,52 intrathyroidal
TSAb-producing B cells may stimulate the release of their cognate
antigen, and disruption of thyroid germinal centres by RTX may
interrupt this positive feedback loop. However, because of the small
number of sera with TRAb levels sufficiently high to allow this kind
of analysis, the findings of a differential effect of RTX on TSAb level
compared with that on TRAbs need to be confirmed in a larger
study.49
The data presented by Salvi et al.47 indicate an approximately
65% decrease in TPOAb levels by 50 weeks following RTX
administration, findings congruent with our results.49 While the
effect of RTX on anti-thyroglobulin antibodies was not examined
by El Fassi et al.,46 Salvi et al.47 indicated a non-significant 50%
decline in those antibodies within 8 weeks in the patients treated
with RTX. To date, no reports have appeared concerning poten-
tial effects of RTX on other autoantibodies in TAO, including
those against collagen XII53 or insulin-like growth factor recep-
tor.54
Treatment with RTX, usually in combination with cyclophos-
phamide and prednisolone, generally has modest effects on levels
of circulating IgG and IgA. This includes antimicrobial and self-
directed antibodies.49,55–61 In contrast, RTX often lowers levels of
IgM, including rheumatoid factor.61,62 We know now that plasma
cells can be especially long lived,63 which explains why detectable
levels of IgGs persist, even during B-cell depletion. On the other
hand, levels of some autoantibodies, including anti-dsDNA, anti-
C1q and ANCA, can fall markedly after initiation of RTX treat-
ment.60,61,64
The effect of rituximab on TAO
When considering evidence for a positive impact of RTX on the
clinical course of TAO, concerns similar to those articulated with
regard to the glandular component of GD appear to apply. In addi-
tion, the well-recognized limitations in evaluating and classifying
patients with TAO confound any assessment of the studies per-
formed. These barriers merit attention.65 In the three studies, only
17 patients with TAO were included9,47,66 (Table 1). While these
studies report remarkable improvement in the activity and severity
of TAO following RTX therapy, the substantial limitations of all
three preclude drawing any firm conclusions.
The study of El Fassi et al.9 included two female ex-smokers who
had previously received both glucocorticoids and retrobulbar irra-
diation. Both were euthyroid and had completed their course of
steroids at time of RTX therapy. Eight months after RTX adminis-
tration, the clinical activity score (CAS) had decreased from 6 to 2
in one patient and from 5 to 1 in the other. Disease severity (soft
tissue changes and eye motility) was significantly improved in both
patients, as was proptosis. Effects were evident as early as 1 month
post-therapy and have lasted for more than 1 year without addi-
tional therapy.
Seven of nine patients followed prospectively by Salvi et al.47 had
active TAO, while the others manifested lid signs. Evaluated
7 months after RTX therapy, the CAS decreased from a mean of
4Æ7–1Æ8. Disease severity, including soft tissue inflammation, was
reduced significantly and ocular motility improved. The effect was
evident at 1 month after therapy and has lasted for at least 1 year.
Most recently, we reported that in six patients unresponsive to
glucocorticoid therapy and presenting with severe and active TAO,
RTX had a rapid and sustained therapeutic effect on both activity
and severity of TAO.66 CAS decreased from a mean of 5Æ3–1Æ8 after
8 weeks had elapsed following therapy and continued for an aver-
age of 6 months. Four of the six patients had presented with optic
neuropathy. Visual acuity improved in all within 4 weeks of RTX
therapy and returned to premorbid levels within 2 months. Taper-
ing of glucocorticoids, given concomitantly in all patients, was uni-
formly well-tolerated. Not surprisingly none of the patients
experienced improvement in extra-ocular motility or proptosis. In
contrast to the other articles, failure of RTX in improving TAO in a
single patient was recently reported.67
Taken together, these limited studies on a heterogeneous cohort
of patients suggest that RTX may prove efficacious in those patients
with TAO who are most needy. But controlled studies must now be
conducted. In view of the high cost of RTX and the reportedly seri-
ous side effects, such studies must focus on both efficacy and on
carefully defining the subgroup of patients most appropriate for
inclusion. Awaiting such studies, it is our opinion that RTX be used
when evidence-based therapy has failed or is contraindicated.
Possible mechanisms for RTX action
A series of animal studies24–26,68,69 and clinical trials of RTX in
T-cell-mediated autoimmunity27,28 has taught us that RTX targets
the APC functions of B cells. It remains likely that abolished
antigen presentation by B cells also plays a significant role in the
clinical improvement observed in GD and TAO following RTX
therapy. In TAO, attenuation of antigen-presentation by B cells
seems a plausible explanation for the clinical effect of RTX. This is
entirely consistent with the view that TAO is T-cell mediated, and
because a role for auto-antibodies in the pathogenesis of this
component of GD has yet to be established convincingly.
RTX therapy alters the behaviour of other immune cells besides
B cells. For instance, administration of the drug to patients with RA
up-regulated expression of B-cell-activating factor, IL-10 and
CD86 in monocyte-derived macrophages.70 Another important
potential aspect of RTX actions on immune function concerns its
impact on B-cell cytokine production. In patients with RA, B-cell
depletion results in a dramatic elevation of serum IL-8 levels.71 The
markedly elevated levels of IL-5, IL-6 and IL-10 found in untreated
individuals with HIV infections were reduced following RTX ther-
apy.72 Serum TNF-a levels were also reduced within 2 days of RTX
administration to patients with systemic lupus erythematosus
(SLE).73
Of particular relevance for GD, it is conceivable that B cells sup-
port inflammatory plasma cell niches where the production of
auto-antibodies occurs and that RTX therapy destroys such inflam-
matory niches.74 This mechanism might enhance the turnover of
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autoantibody-producing plasma cells, and in so doing reduce auto-
antibody production. The available data from three studies of RTX
in GD or TAO suggest that TRAb levels decrease following B-cell
depletion to a similar extent to that seen following treatment with
MMI or prednisolone.46–48 However, the prolonged remission
observed in patients with low baseline TRAb levels indicates that
pathogenic antibody specificities may have been temporarily
removed from the repertoire of the repopulating B cells. A similar
phenomenon was observed in SLE where RTX treatment causes a
temporary decrease in the proportion of specific CD27+ memory B
cells producing disease-associated auto-antibodies encoded by the
VH4-34-gene.
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Side effects of rituximab
In deciding on disease management, the potential side effects of
RTX therapy need to be balanced with disease severity and suitabil-
ity of therapeutic alternatives. In uncomplicated GD, inexpensive
and time-proven therapies make the use of RTX relatively unattrac-
tive.4,76,77 The threshold for its use differs substantially in severe
TAO, where our options are considerably more limited. All studies
examining RTX therapy in GD and TAO have reported the occur-
rence of side effects, but with varying prevalence and severity.42,46–
48,66 Pretreating with 1 g of acetaminophen and 2 mg of i.v.
clemastine, El Fassi et al.46 encountered side effects in 5 of 10
patients following the initial RTX infusion. Four patients devel-
oped hypotension, two became nauseated, one became febrile,
another complained of chills and one developed sinus tachycardia.
Two of these patients received antihistamine and one was given
glucocorticoids. Four days after the second infusion, two patients
developed serum sickness (joint pain and fever), one of whom sub-
sequently developed diarrhoea and iridocyclitis a year later.
Another had recurrent fever, symmetric polyarthritis and ulcerative
colitis diagnosed 1–2 months after the second infusion.42 The latter
process is remarkable as administration of RTX to patients with
ulcerative colitis has lead to its exacerbation.78 This finding sug-
gests that B cells might play a protective role mediated by IL-10,
which may then override any detrimental aspects of B-cell function.
Therefore, RTX should be administered with caution in patients
with concomitant inflammatory bowel disease.
In the study of Salvi et al.47, 1 g of paracetamol and 10 mg chlor-
phenamine were given as pretreatment. Only three of nine patients
had mild side effects during the first RTX infusion, such as a mild
fever, which was treated by 100 mg hydrocortisone i.v. Heemstra
et al.48 gave 10 mg dexamethasone and 2 mg clemastine i.v. and
reported no other side effects than temporary joint pain in two
patients who had no clinical signs. Khanna et al.66 administered
100 mg i.v. methylprednisolone, 1 g acetaminophen and 50 mg
diphenhydramine as premedication. One patient developed a uri-
nary tract infection, one had worsening hypertension and one died
from sudden cardiac arrest 3 months after the second infusion.
The relatively small numbers of cases thus far reported make
drawing any valid conclusions impossible with regard to efficacy or
side effects. Reconciling the types and severities of the complica-
tions thus far encountered in patients with GD with those experi-
enced in other diseases where RTX is administered may provide
valuable insights. Until results from a randomized study with stan-
dardized recruitment become available, any assessment of side
effects remains difficult. These studies are apparently under-
way,79,80 although their scope and size may prove inadequate.
Unfortunately, several obstacles remain concerning the evaluation
of clinical efficacy in TAO.65 Until these are resolved, interpretation
of any clinical trial will be confounded with the same problems that
have plagued this field for decades.
Conclusions and areas for future research
Treatment of Graves’ disease (GD) complicated by thyroid-associ-
ated ophthalmopathy (TAO) remains difficult and imprecise, lar-
gely because we have not yet determined many aspects of disease
pathogenesis. On the horizon is the potential for utilizing several
highly specific agents that target components of the immune sys-
tem.79,80 The advantage they appear to offer results from their tar-
geted mechanisms of action. Among them, rituximab (RTX) may
prove effective and seems to interrupt many aspects of the immune
response that we predict would underlie this disease. Clearly, the
clinical assessment is in its very early stages and will require addi-
tional and more robust trials. But if we are to approach treatment
of this disease in a more systematic manner, we must learn much
more about its cause, identify the aberrant molecular and cellular
events that lead to its manifestations and to develop animal models
in which we might screen drug candidates.79 In addition, we can
almost certainly gain from the experience in developing therapies
for related autoimmune diseases, where greater progress is being
made.
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